Express Scripts stops covering key Big Pharma drugs on clinical, cost-effectiveness grounds

Tracy Staton

A few weeks ago, Novo Nordisk said it had lost ' business on two of its top , Victoza and NovoLog. Well, that was just part of the action at the pharmacy benefits manager. More than 40 other , including some of Big 's newest growth prospects, got the same treatment. And ironically, drugmakers may have their own marketing techniques to blame.

FiercePharma News

Share This Post

Related Articles

Leave a Reply

© 2019 Global Regulatory Science. All rights reserved. Site Admin · Entries RSS · Comments RSS